ALBANY, N.Y. , Nov. 8, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, appointed Matthew Kapusta , Senior Vice President of Business Development,

Results Meet Company Guidance; Management Reiterates Full Fiscal Year Guidance Authorizes Stock Repurchase Program ALBANY, N.Y. , Oct. 6, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery,

ALBANY, N.Y. , Oct. 3, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the U.S. District Court for the Northern District of New York has

Multi-Center, Clinical Trial Using Irreversible Electroporation for the Treatment of Early-Stage HCC (ONC-205) Includes 26 Patients From Five Sites

ALBANY, N.Y. , Sept. 29, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2012 first quarter financial

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that Scott Solano , Senior Vice President and Chief Technology Officer, has resigned

ALBANY, N.Y. , Sept. 12, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, has appointed Alan Panzer , 50, as Senior Vice President and General Manager of

ALBANY, N.Y. , Sept. 6, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, will present at CL King's 9th Annual Best Ideas Conference on Tuesday, September 13, 2011 ,

ALBANY, N.Y. , Aug. 25, 2011 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, will present at the Stifel Nicolaus Healthcare Conference on Thursday, September 8, 2011 ,

ALBANY, N.Y. --(BUSINESS WIRE)-- The Board of Directors of AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, appointed Joseph M. DeVivo President and Chief Executive Officer,

Q4 Net Sales of $56.4 Million ; 2011 Net Sales of $216.0 Million Q4 NanoKnife ® System Sales Up 170% versus Year Ago Quarter ; International Sales Rise 28% versus Year Ago Quarter Two Non-Cash Charges Totaling $6.4 Million Recorded in Q4 Q4 EPS of $0.11 Prior to Charges and $0.03 Loss Per

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report its fiscal 2011 fourth quarter and full year financial

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported preliminary unaudited financial results for the fiscal 2011 fourth quarter, as

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ: ANGO) has expanded its VenaCure EVLT ® System product offering with the global launch of the new VenaCure ® 1470nm laser to treat varicose veins with greater energy efficiency. "Our VenaCure 1470 endovenous laser has shown to be

Longer NeverTouch ® Gold-Tip Fiber with TRE-Sheath ® Introducer Gives More Options ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO) announced today the launch of the new 90 cm NeverTouch ® procedure kit featuring a longer TRE-Sheath ® introducer to gain vascular

U.S. distribution contract for LC Beads ™ to expire on December 31, 2011 FDA approves IDE for NanoKnife ® System study in prostate cancer Company expects to submit IDE for NanoKnife System study in pancreatic cancer by mid-June Oncology/Surgery division to enhance focus on NanoKnife, and

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that executive management will present at the following investor conferences in

Net Sales of $54.6 Million ; NanoKnife ® System Net Sales of $1.9 Million Net Income of $3.8 Million , or $0.15 EPS Operating Cash Flow of $10.3 Million Updates Fiscal Year 2011 Guidance Conference Call Today at 4:30 p.m. Eastern Time ALBANY, N.Y.

Company's New DuraMax VascPak™ Kit Targets Vascular Access Centers ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO) announced today the U.S. launch and initial shipments of the next generation DuraMax ® stepped-tip chronic dialysis catheter and the DuraMaxVP (VascPak™)

ALBANY, N.Y. --(BUSINESS WIRE)-- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access and the treatment of peripheral vascular disease and cancer, today announced that it will report its fiscal 2011 third quarter financial results on